Cost-Effectiveness of the Diabetes Care Protocol, a Multifaceted Computerized Decision Support Diabetes Management Intervention That Reduces Cardiovascular Risk

被引:26
作者
Cleveringa, Frits G. W. [1 ]
Welsing, Paco M. J. [1 ]
van den Donk, Maureen [1 ]
Gorter, Kees J. [1 ]
Niessen, Louis W. [2 ,3 ,4 ]
Rutten, Guy E. H. M. [1 ]
Redekop, William K. [2 ]
机构
[1] Univ Med Ctr, Julius Ctr Hlth Sci & Primary Care, Utrecht, Netherlands
[2] Erasmus Univ, Dept Hlth Policy & Management, Rotterdam, Netherlands
[3] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, Baltimore, MD USA
[4] Univ E Anglia, Sch Med Policy & Practice, Norwich NR4 7TJ, Norfolk, England
关键词
CLUSTER-RANDOMIZED-TRIAL; BLOOD-GLUCOSE CONTROL; FOLLOW-UP; TYPE-2; OUTCOMES; DISEASE; BENEFITS; MODEL;
D O I
10.2337/dc09-1232
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVE - The Diabetes Care Protocol (DCP), a multifaceted Computerized decision support diabetes management intervention, reduces cardiovascular risk Of type 2 diabetic patients. We performed a cost-effectiveness analysis of DCP from a Dutch health care perspective. RESEARCH DESIGN AND METHODS - A cluster randomized trial provided data of DCP versus usual care. The I-year follow-up patient data were extrapolated using a modified Dutch microsimulation diabetes model, computing individual lifetime health-related costs, and health effects. incremental costs and effectiveness (quality-adjusted life-years [QALYs]) were estimated using multivariate generalized estimating equations to correct for practiice-level clustering and confounding. Incremental cost-effectiveness ratios (ICERs) were calculated and cost-effectiveness acceptability curves were created. Stroke costs were calculated separately. Subgroup analyses examined patients with and without cardiovascular disease (CVD+ or CVD-patients, respectively). RESULTS - Excluding Stroke, DCP patients lived longer (0.14 life-years, P = NS), experienced more QALYs (0.037, P = NS), and incurred higher total costs ((sic)1,415, P = NS), resulting in an ICER of (sic)38,243 per QALY gained. The likelihood Of Cost-effectiveness given a willingness-to-pay threshold of (sic)20,000 per QALY gained is 30%. DCP had a more favorable effect on CVD+ patients (ICER = (sic)14,814) than for CVD - Patients (ICER = (sic)121,285). Coronary heart disease costs were reduced ((sic)-587, P < 0.05). CONCLUSIONS - DCP reduces cardiovascular risk, resulting in only a slight improvement in QALYs, lower CVD costs, but higher total costs, With a high cost-effectiveness ratio. Cost-effective care can be achieved by focusing on cardiovascular risk factors in type 2 diabetic patients with a history of CVD.
引用
收藏
页码:258 / 263
页数:6
相关论文
共 25 条
[1]  
[Anonymous], 2006, HUISARTS WET
[2]   Cost effectiveness of perindopril in reducing cardiovascular events in patients with stable coronary artery disease using data from the EUROPA study [J].
Briggs, Andrew ;
Mihaylova, Borislava ;
Sculpher, Mark ;
Hall, Alistair ;
Wolstenholme, Jane ;
Simoons, Maarten ;
Deckers, Jaap ;
Ferrari, Roberto ;
Remme, Willem J. ;
Bertrand, Michel ;
Fox, Kim .
HEART, 2007, 93 (09) :1081-1086
[3]   Need for differential discounting of costs and health effects in cost effectiveness analyses [J].
Brouwer, WBF ;
Niessen, LW ;
Postma, MJ ;
Rutten, FFH .
BRITISH MEDICAL JOURNAL, 2005, 331 (7514) :446-448
[4]   Benefits of information technology - Enabled diabetes management [J].
Bu, Davis ;
Hook, Julie M. ;
Pan, Eric ;
Cusack, Caitlin M. ;
Walker, Janice ;
Bates, David W. ;
Adler-Milstein, Julia ;
Middleton, Blackford ;
Kendrick, David .
DIABETES CARE, 2007, 30 (05) :1137-1142
[5]   Combined Task Delegation, Computerized Decision Support, and Feedback Improve Cardiovascular Risk for Type 2 Diabetic Patients A cluster randomized trial in primary care [J].
Cleveringa, Frits G. W. ;
Gorter, Kees J. ;
van den Donk, Maureen ;
Rutten, Guy E. H. M. .
DIABETES CARE, 2008, 31 (12) :2273-2275
[6]  
*COLL ZORGV DIEM, 2006, GUID PHARM RES UPD V
[7]   Megatrials in type 2 diabetes. From excitement to frustration? [J].
Del Prato, S. .
DIABETOLOGIA, 2009, 52 (07) :1219-1226
[8]   Patient-centred and professional-directed implementation strategies for diabetes guidelines: a cluster-randomized trial-based cost-effectiveness analysis [J].
Dijkstra, RF ;
Niessen, LW ;
Braspenning, JCC ;
Adang, E ;
Grol, RTPM .
DIABETIC MEDICINE, 2006, 23 (02) :164-170
[9]   Model of Complications of NIDDM .2. Analysis of the health benefits and cost-effectiveness of treating NIDDM with the goal of normoglycemia [J].
Eastman, RC ;
Javitt, JC ;
Herman, WH ;
Dasbach, EJ ;
CopleyMerriman, C ;
Maier, W ;
Dong, F ;
Manninen, D ;
Zbrozek, AS ;
Kotsanos, J ;
Garfield, SA ;
Harris, M .
DIABETES CARE, 1997, 20 (05) :735-744
[10]   Cost-effectiveness of intensified versus conventional multifactorial intervention in type 2 diabetes -: Results and projections from the Steno-2 study [J].
Gaede, Peter ;
Valentine, William J. ;
Palmer, Andrew J. ;
Tucker, Daniel M. D. ;
Lammert, Morten ;
Parving, Hans-Henrik ;
Pedersen, Oluf .
DIABETES CARE, 2008, 31 (08) :1510-1515